Literature DB >> 6959572

Progressive neuromuscular disease in children with chronic cholestasis and vitamin E deficiency: clinical and muscle biopsy findings and treatment with alpha-tocopherol.

M A Guggenheim, S P Ringel, A Silverman, B E Grabert, H E Neville.   

Abstract

We have studied four children (ages 6 to 17 years) with chronic cholestasis who developed a slowly progressive neuromuscular disease characterized by ataxia, dysmetria, areflexia, loss of vibratory sensation, and a variable ophthalmoplegia. Serum vitamin E concentrations were low in all patients prior to treatment (0.17-2.0 mg/g cholesterol, normal greater than 3 mg/g). Muscle histochemical studies showed prominent yellow autofluorescence, basophilic cytoplasmic inclusions which stain with esterase and acid phosphatase, and occasional necrotic fibers. Ultrastructural findings consisted of increased number and size of membrane-bound dense bodies (lysosomes), membranous whorls, and autophagic vacuoles. Intramuscular injections of all-rac-alpha-tocopherol (0.55-1.42 mg/kg per 24 hours based on individualized pharmacokinetic data) were required in three patients to achieve normal serum vitamin E values. High-dose (32 mg/kg per 24 hours) oral supplementation was effective in one patient. After normalization of serum vitamin E concentrations for 12 to 20 months, the neurologic disease has improved in all four patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6959572     DOI: 10.1111/j.1749-6632.1982.tb31235.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  13 in total

Review 1.  Nutrition and growth in patients with chronic liver disease.

Authors:  D A Kelly
Journal:  Indian J Pediatr       Date:  1995 Sep-Oct       Impact factor: 1.967

2.  High-density lipoprotein (HDL3)-associated alpha-tocopherol is taken up by HepG2 cells via the selective uptake pathway and resecreted with endogenously synthesized apo-lipoprotein B-rich lipoprotein particles.

Authors:  D Goti; H Reicher; E Malle; G M Kostner; U Panzenboeck; W Sattler
Journal:  Biochem J       Date:  1998-05-15       Impact factor: 3.857

Review 3.  Active oxygen in neuromuscular disorders.

Authors:  A Davison; G Tibbits; Z G Shi; J Moon
Journal:  Mol Cell Biochem       Date:  1988-12       Impact factor: 3.396

4.  Muscle-specific overexpression of lipoprotein lipase in transgenic mice results in increased alpha-tocopherol levels in skeletal muscle.

Authors:  W Sattler; S Levak-Frank; H Radner; G M Kostner; R Zechner
Journal:  Biochem J       Date:  1996-08-15       Impact factor: 3.857

5.  Lipofuscin accumulation in extraocular muscle of rats deficient in vitamins E and A.

Authors:  R K Herrmann; W G Robison; J G Bieri; M Spitznas
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1985       Impact factor: 3.117

6.  Myopathy in vitamin E deficient rats: muscle fibre necrosis associated with disturbances of mitochondrial function.

Authors:  P K Thomas; J M Cooper; R H King; J M Workman; A H Schapira; M A Goss-Sampson; D P Muller
Journal:  J Anat       Date:  1993-12       Impact factor: 2.610

Review 7.  Etiologic factors and pathologic alterations in selenium-vitamin E deficiency and excess in animals and humans.

Authors:  J F Van Vleet; V J Ferrans
Journal:  Biol Trace Elem Res       Date:  1992 Apr-Jun       Impact factor: 3.738

8.  Sarcolipin and ubiquitin carboxy-terminal hydrolase 1 mRNAs are over-expressed in skeletal muscles of alpha-tocopherol deficient mice.

Authors:  Vihas T Vasu; Sean Ott; Brad Hobson; Vania Rashidi; Saji Oommen; Carroll E Cross; Kishorchandra Gohil
Journal:  Free Radic Res       Date:  2009-02

9.  Bovine milk lipoprotein lipase transfers tocopherol to human fibroblasts during triglyceride hydrolysis in vitro.

Authors:  M G Traber; T Olivecrona; H J Kayden
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

Review 10.  Dosage and formulation issues: oral vitamin E therapy in children.

Authors:  Tone Westergren; Betty Kalikstad
Journal:  Eur J Clin Pharmacol       Date:  2009-10-13       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.